Loading market dashboard
Nuwellis, Inc.
NUWEHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
MINNEAPOLIS, June 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces the pricing of a public offering of 20,000,000 shares of its common stock ("Common Stock") (or pre-funded warrants in lieu thereof) with accompanying warrants to purchase common stock for gross proceeds of approximately $6 million (the “Offering”).
Proposal would extend treatment access to pediatric patients weighing 5 kg and above Proposal would extend treatment access to pediatric patients weighing 5 kg and above
Nuwellis, Inc. (NUWE) Q1 2026 Earnings Call Transcript
MINNEAPOLIS, May 12, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the first quarter ended March 31, 2026.
MINNEAPOLIS, May 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will report its financial results for the first quarter ended March 31, 2026 premarket on Tuesday, May 12, 2026. The Company will subsequently host a conference call and webcast at 9:00 AM ET on May 12, 2026 to discuss its financial results and provide an update on the Company's performance.
MINNEAPOLIS, April 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlights a case study presented by the University of Iowa Stead Family Children's Hospital at the 46th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT), held April 22-25, 2026, in Toronto, Canada.
Poster presentation showcased continued advancement of Aquadex therapy in pediatric applications, underscoring continued need for adoption in fluid management in pediatric heart failure Poster presentation showcased continued advancement of Aquadex therapy in pediatric applications, underscoring continued need for adoption in fluid management in pediatric heart failure
MINNEAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new patent covering its novel dual lumen midline catheter technology designed for use in ultrafiltration therapies. This next-generation catheter incorporates advanced design elements to optimize blood flow dynamics during therapy.
Medical technology company to showcase Aquadex ultrafiltration therapy for fluid removal in Booth 530 Medical technology company to showcase Aquadex ultrafiltration therapy for fluid removal in Booth 530
MINNEAPOLIS, April 21, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on solutions for patients with cardiorenal conditions, today announced a software update to its Aquadex SmartFlow® ultrafiltration platform. The update is designed to improve usability, streamline clinical workflow, and enhance overall user experience.
MINNEAPOLIS, April 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the return of three former team members: Liby Cielo, Principal Account Manager; Meredith Stein, Senior Clinical Education Specialist; and Scott Campbell, Area Vice President, Sales. The addition of these returning team members reflects Nuwellis' continued focus on strengthening its commercial and clinical capabilities and supporting hospitals treating patients with complex cardiorenal conditions.
MINNEAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it has retained CORE IR, a leading investor relations, public relations, and strategic advisory firm, to assist the Company with public relations, shareholder communications, and social media management services.
Strategic expansion of field coverage enhances hospital engagement and increases access to Aquadex® therapy across the region Strategic expansion of field coverage enhances hospital engagement and increases access to Aquadex® therapy across the region
Pediatric footprint expands to 47 centers nationwide, including six of the nation's top 10 children's hospitals Pediatric footprint expands to 47 centers nationwide, including six of the nation's top 10 children's hospitals
MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the completion of its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill patients. Rendiatech has no commercial operations and was formed to acquire certain assets of RenalSense Ltd.
Nuwellis, Inc. (NUWE) Q4 2025 Earnings Call Transcript
MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Nuwellis (NASDAQ: NUWE - Get Free Report) is expected to release its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect Nuwellis to post earnings of ($1.56) per share and revenue of $2.31 million for the quarter. Investors can find conference call details on the company's upcoming Q4 2025 earning report page
